Search company, investor...
GenomeQuest company logo


Founded Year



Series C | Alive

Total Raised




Last Raised

$3.1M | 14 yrs ago

About GenomeQuest

GenomeQuest aims to offer a self-updating, reliable and secure genomic search solution that integrates biological sequence search capabilities, analytics, and patent content from dozens of private and public sources worldwide into a single powerful, web-based solution.

Headquarters Location

1700 West Park Drive Suite 260

Westborough, Massachusetts, 01581,

United States


Missing: GenomeQuest's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: GenomeQuest's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing GenomeQuest

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GenomeQuest is included in 1 Expert Collection, including Omics.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Latest GenomeQuest News

Aptean Supports Research to Fight COVID-19 Pandemic by Offering Worldwide Complimentary GenomeQuest Usage to Scientific Community

Mar 23, 2020

Leading IP Sequence Search Resource Expands Access to the World's Largest Intellectual Property Sequence Database | Source: Aptean Inc. ALPHARETTA, Ga., March 23, 2020 (GLOBE NEWSWIRE) -- To support the scientific community researching the COVID-19 pandemic, also referred to as the novel Coronavirus, Aptean , a global provider of mission-critical enterprise software solutions, announced today its commitment to fighting the deadly virus through the worldwide use of its platform, GenomeQuest. Aptean’s GenomeQuest is the world’s largest intellectual property sequence database that uses proprietary, state-of-the-art sequence comparison algorithms for in-depth search and analysis. Since February, Aptean has been offering cost-free, limited-access GenomeQuest accounts to scientists researching the virus in the countries most impacted by COVID-19. The company is now extending this offer to companies around the world, providing essential genetic information and analysis tools to support their efforts to diagnose and cure the disease. This access can also aid in potentially creating vaccines to prevent similar outbreaks in the future. “The novel Coronavirus (COVID-19) is continuing to spread worldwide, creating global concern and uncertainty. As scientists work to come up with a vaccine for the disease, we’ve utilized the genetic sequence information in the NCBI virus database, in conjunction with GenomeQuest, our intellectual property sequence search tool, to provide scientists with a unique set of benefits critical to support the research,” says Martin Wagstaff, Group Vice President of Compliance Solutions at Aptean. Through GenomeQuest, researchers can:   Utilize the product’s best-in-class sequence analysis tools by securely uploading their own proprietary sequence data—allowing users to leverage their own data in tandem with publically available COVID-19 sequence data inside a secure, confidential environment; Collect data insights on a single-base level or over a large amount of data—more thorough analyses can be conducted on GenomeQuest than on public platforms, resulting in a shorter time frame to data insights; Search the latest information with access to nearly 450 million patent sequences, many of which are not available on public sites. Wagstaff adds, “GenomeQuest also has a unique group of search algorithms and the unique capability to identify very specific variant sequences, neither of which is available elsewhere.” Made available early February, this offering will remain accessible to researchers as long as it is relevant to the status of the outbreak. The database will be updated as new information comes available. For more information on Aptean GenomeQuest, click here . About Aptean Aptean is a global provider of mission-critical, industry-specific software solutions. Aptean’s purpose-built ERP and supply chain management solutions help address the unique challenges facing process and discrete manufacturers, distributors, and other focused organizations. Aptean’s compliance solutions are built for companies serving specific markets such as finance, healthcare, biotech, and pharmaceuticals. Over 4,000 organizations in more than 20 industries across 54 countries trust Aptean’s solutions at their core to assist with running their operations. To learn more about Aptean and the markets we serve, visit . Aptean is a trademark of Aptean, Inc. All other company and product names may be trademarks of the respective companies with which they are associated. For Media Inquiries Please Contact Nicole O’Rourke

GenomeQuest Frequently Asked Questions (FAQ)

  • When was GenomeQuest founded?

    GenomeQuest was founded in 1998.

  • Where is GenomeQuest's headquarters?

    GenomeQuest's headquarters is located at 1700 West Park Drive, Westborough.

  • What is GenomeQuest's latest funding round?

    GenomeQuest's latest funding round is Series C.

  • How much did GenomeQuest raise?

    GenomeQuest raised a total of $11.34M.

  • Who are the investors of GenomeQuest?

    Investors of GenomeQuest include Activate Venture Partners, Mosaix Ventures, Cross Atlantic Capital Partners, Cross Atlantic Partners, SG Asset Management and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.